A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

被引：0
|
作者：
Rosenthal, Allison C. [1 ]
Dueck, Amylou Constance [1 ]
Gano, Katherine [1 ]
Nichols, Craig [2 ]
Johnson, Daniel [1 ]
Toro, Angela [1 ]
Reddy, Sravan Nagi [1 ]
Slack, James L. [1 ]
Leis, Jose F. [1 ]
Northfelt, Donald W. [1 ]
Bergsagel, P. Leif [2 ]
Tiedemann, Rodger [3 ]
Johnston, Patrick B. [2 ]
Habermann, Thomas M. [2 ]
Witzig, Thomas E. [2 ]
Reeder, Craig B. [1 ]
机构：
[1] Mayo Clin Arizona, Scottsdale, AZ USA
[2] Mayo Clin, Rochester, MN USA
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.4748.4748
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
    Sonbol, Mohamad Bassam
    Hilal, Talal
    Dueck, Amylou C.
    Rosenthal, Allison C.
    Conley, Christopher R.
    Kosiorek, Heidi E.
    Ginos, Brenda F.
    Gano, Katherine M.
    Nichols, Craig S.
    Leis, Jose F.
    Johnston, Patrick B.
    Habermann, Thomas M.
    Northfelt, Donald W.
    Bergsagel, Peter Leif
    Inwards, David J.
    Witzig, Thomas E.
    Ansell, Stephen M.
    Reeder, Craig B.
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2128 - 2134
  • [2] Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma
    Lee, Hun Ju
    Romaguera, Jorge E.
    Feng, Lei
    Desai, Aakash P.
    Zhang, Liang
    Fanale, Michelle
    Samaniego, Felipe
    Hagemeister, Fredrick B.
    Fayad, Luis E.
    Rodriguez, Maria A.
    Medeiros, Jeffrey L.
    Hartig, Kimberly
    Nomie, Krystle
    Ahmed, Makhdum
    Badillo, Maria
    Ye, Haige
    Oki, Yasuhiro
    Lin, Pei
    Nastoupil, Loretta
    Westin, Jason
    Wang, Michael
    ONCOLOGIST, 2017, 22 (05): : 549 - 553
  • [3] Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)
    Romaguera, Jorge E.
    Fanale, Michelle A.
    Samaniego, Felipe
    Fayad, Luis E.
    Hagemeister, Fredrick B.
    McLaughlin, Peter
    Rodriguez, Maria Alma
    Weaver, Pam
    Hartig, Kim
    Badillo, Maria
    Kwak, Larry W.
    Younes, Anas
    Pro, Barbara
    Wang, Michael
    BLOOD, 2013, 122 (21)
  • [4] Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma
    Shin, Junghoon
    Lee, Ji Yun
    Lee, Gyeong-Won
    Kim, Won Seog
    Park, Yong
    Do, Young Rok
    Kim, Dae Sik
    Kim, Ki Hwan
    Choi, Yoon Seok
    Byun, Ja Min
    Hong, Junshik
    Kim, Inho
    Yoon, Sung-Soo
    Koh, Youngil
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (06) : E54 - E57
  • [5] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma
    Baiocchi, Robert A.
    Alinari, Lapo
    Lustberg, Mark E.
    Lin, Thomas S.
    Porcu, Pierluigi
    Li, Xiaobai
    Johnston, Jeffrey S.
    Byrd, John C.
    Blum, Kristie A.
    CANCER, 2011, 117 (11) : 2442 - 2451
  • [6] Phase 2 Trial of Bortezomib in Combination With Rituximab Plus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Alternating With Bortezomib, Rituximab, Methotrexate, and Cytarabine for Untreated Mantle Cell Lymphoma
    Romaguera, Jorge E.
    Wang, Michael
    Feng, Lei
    Fayad, Luis E.
    Hagemeister, Frederick
    McLaughlin, Peter
    Rodriguez, M. Alma
    Fanale, Michelle
    Orlowski, Robert
    Kwak, Larry W.
    Neelapu, Sattva
    Oki, Yasuhiro
    Pro, Barbara
    Younes, Anas
    Samaniego, Felipe
    Fowler, Nathan
    Hartig, Kimberly
    Valentinetti, Marisa
    Smith, Judy
    Ford, Peggy
    Naig, Adam
    Medeiros, L. Jeffrey
    Kantarjian, Hagop M.
    Goy, Andre
    CANCER, 2018, 124 (12) : 2561 - 2569
  • [7] Phase II trial of bortezomib in mantle cell lymphoma
    Belch, A
    Kouroukis, CT
    Crump, M
    Sehn, L
    Gascoyne, R
    Klasa, R
    Powers, J
    Eisenhauer, E
    BLOOD, 2004, 104 (11) : 175A - 176A
  • [8] A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma
    Flinn, Ian W.
    Ervin, Thomas J.
    Boccia, Ralph V.
    Flora, Douglas B.
    Cuevas, J. Daniel
    Thompson, Dana S.
    Shipley, Dianna L.
    Berdeja, Jesus G.
    BLOOD, 2015, 126 (23)
  • [9] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
  • [10] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
12345